Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133 Milan, Italy.
Neurol Sci. 2011 Nov;32 Suppl 2:S251-3. doi: 10.1007/s10072-011-0799-6.
Bevacizumab has been introduced in the management of high-grade gliomas after preliminary studies that showed an acceptable safety and a marked increase in clinico-radiological responses in comparison with second-line chemotherapy. The objective is to synthetically review the present use of bevacizumab--alone or in combination--in the context of recurrent high-grade glioma and highlight the future developments. The methodology of this study is to analyse and discuss relevant literature studies using bevacizumab in recurrent high-grade glioma. Bevacizumab may be used as single-agent therapy in recurrent high-grade glioma, with good clinico-radiological responses having little effect on survival. The open questions and developments include new MRI criteria for evaluation of response to anti-angiogenic agents, the identification of putative factors predicting response/failure of bevacizumab and the introduction of bevacizumab in first-line management of high-grade glioma.
贝伐珠单抗已被引入高级别脑胶质瘤的治疗中，初步研究表明，与二线化疗相比，贝伐珠单抗具有可接受的安全性和显著增加的临床-影像学反应。目的是综合回顾贝伐珠单抗在复发性高级别脑胶质瘤中的目前应用，并强调未来的发展。本研究的方法是分析和讨论使用贝伐珠单抗治疗复发性高级别脑胶质瘤的相关文献研究。贝伐珠单抗可作为复发性高级别脑胶质瘤的单一药物治疗，具有良好的临床-影像学反应，但对生存几乎没有影响。尚未解决的问题和未来的发展包括用于评估抗血管生成药物反应的新 MRI 标准、鉴定可能预测贝伐珠单抗反应/失败的因素以及在高级别脑胶质瘤的一线治疗中引入贝伐珠单抗。
